Earnings Preview: Viking Therapeutics
Portfolio Pulse from Benzinga Insights
Viking Therapeutics (NASDAQ:VKTX) is scheduled to release its quarterly earnings report on February 7, 2024, with an estimated EPS of $-0.26. Analysts and investors are particularly interested in the company's guidance for future growth. Viking Therapeutics' stock performance has been strong, with a 150.16% increase over the last 52 weeks. The company's past earnings performance shows a mixed impact on its stock price, with the last quarter's miss resulting in a 9.42% drop.
February 06, 2024 | 3:03 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Viking Therapeutics is expected to announce its quarterly earnings with an estimated EPS of $-0.26. Investors are keen on the company's future guidance. The stock has seen a significant increase over the past year, but past earnings have shown that misses can lead to price drops.
The estimated EPS and the emphasis on future guidance suggest a neutral outlook for VKTX's short-term stock price. Historical data indicates that earnings misses have led to price drops, but the overall positive performance over the past year and the interest in future guidance could stabilize the stock price.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100